FDA has provided general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity for the duration of the COVID-19 public health emergency. This document updates the guidance of the same title issued in December 2020 (previous versions September, July, June, May, April, and March 2020).
Download the updated guidance here.